BR112015018549A8 - métodos de tratamento de deficiência de ferro - Google Patents

métodos de tratamento de deficiência de ferro

Info

Publication number
BR112015018549A8
BR112015018549A8 BR112015018549A BR112015018549A BR112015018549A8 BR 112015018549 A8 BR112015018549 A8 BR 112015018549A8 BR 112015018549 A BR112015018549 A BR 112015018549A BR 112015018549 A BR112015018549 A BR 112015018549A BR 112015018549 A8 BR112015018549 A8 BR 112015018549A8
Authority
BR
Brazil
Prior art keywords
methods
iron deficiency
maintain
subject
ferric pyrophosphate
Prior art date
Application number
BR112015018549A
Other languages
English (en)
Other versions
BR112015018549A2 (pt
Inventor
Gupta Ajay
Original Assignee
Charak Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50097899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015018549(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Charak Llc filed Critical Charak Llc
Publication of BR112015018549A2 publication Critical patent/BR112015018549A2/pt
Publication of BR112015018549A8 publication Critical patent/BR112015018549A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

abstract the invention provides for methods of treating iron deficiency and methods of reducing or eliminating the dose of erythropoiesis stimulating agent for increasing or maintaining hemoglobin levels in the target range in a subject suffering from anemia comprising administering soluble ferric pyrophosphate in an amount effective to maintain or increase hgb levels in the subject. tradução do resumo resumo métodos de tratamento de deficiência de ferro com pirofosfato férrico solúvel a invenção fornece métodos de tratamento de deficiência de fer-ro e métodos para reduzir ou eliminar a dose de agente estimulador da eri-tropoiese para aumentar ou manter os níveis de hemoglobina no intervalo alvo em um sujeito que sofre de anemia compreendendo a administração de pirofosfato férrico solúvel em uma quantidade eficaz para manter ou au-mentar níveis de hgb no sujeito.
BR112015018549A 2013-02-01 2014-02-01 métodos de tratamento de deficiência de ferro BR112015018549A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759531P 2013-02-01 2013-02-01
PCT/US2014/014341 WO2014121155A1 (en) 2013-02-01 2014-02-01 Methods of treating iron deficiency with soluble ferric pyrophosphate

Publications (2)

Publication Number Publication Date
BR112015018549A2 BR112015018549A2 (pt) 2017-07-18
BR112015018549A8 true BR112015018549A8 (pt) 2018-01-30

Family

ID=50097899

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018549A BR112015018549A8 (pt) 2013-02-01 2014-02-01 métodos de tratamento de deficiência de ferro

Country Status (20)

Country Link
US (3) US20150366907A1 (pt)
EP (2) EP3789034A1 (pt)
JP (3) JP2016507527A (pt)
KR (1) KR102236714B1 (pt)
CN (2) CN107007624A (pt)
AU (3) AU2014212127A1 (pt)
BR (1) BR112015018549A8 (pt)
CA (1) CA2900043A1 (pt)
CL (1) CL2015002171A1 (pt)
EA (1) EA032407B1 (pt)
HK (1) HK1215185A1 (pt)
IL (1) IL240257A0 (pt)
MX (1) MX370139B (pt)
NI (1) NI201500100A (pt)
PE (1) PE20151751A1 (pt)
PH (1) PH12015501708A1 (pt)
SG (1) SG11201506022VA (pt)
TW (1) TW201517913A (pt)
WO (1) WO2014121155A1 (pt)
ZA (1) ZA201506364B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861304B1 (en) 2012-06-15 2018-08-08 Symrise AG Compositions comprising hyaluronan biosynthesis promoting agents
JP6578293B2 (ja) * 2013-11-05 2019-09-18 ロックウェル メディカル，インコーポレイテッド 反応性が低下した患者のエリトロポエチン刺激剤の用量を減少させる方法
US11517555B2 (en) * 2015-09-04 2022-12-06 Rockwell Medical, Inc. Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
CN106581053A (zh) * 2015-10-20 2017-04-26 华仁药业股份有限公司 一种具有补铁功能的腹膜透析液
US20210313024A1 (en) * 2018-08-24 2021-10-07 National University YOKOHAMA National Universty Administration managing apparatus, administration managing method, and program
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
EP4103595A1 (en) * 2020-02-11 2022-12-21 Quest Diagnostics Investments LLC System for determining an underlying cause of anemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
NZ336319A (en) * 1996-12-31 2000-12-22 Ajay Gupta Pharmaceutical composition for non-colloidal iron (ferric) delivery in hemodialysis and peritoneal dialysis patients
US6779648B2 (en) * 2000-07-13 2004-08-24 Psi Sales, Inc. 360 Degree rotatable lifter arm for log singulator
JP2005068055A (ja) * 2003-08-22 2005-03-17 Fujiyakuhin Co Ltd 無機元素含有水性コロイド分散液
US7857977B2 (en) * 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
ES2634142T3 (es) * 2005-12-23 2017-09-26 Ajay Gupta Composición de nutrición parenteral que contiene hierro
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
WO2012094598A2 (en) * 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration

Also Published As

Publication number Publication date
EP2950806B1 (en) 2020-07-15
MX370139B (es) 2019-12-03
US20200276232A1 (en) 2020-09-03
IL240257A0 (en) 2015-09-24
KR102236714B1 (ko) 2021-04-06
KR20160004257A (ko) 2016-01-12
PE20151751A1 (es) 2015-12-03
SG11201506022VA (en) 2015-08-28
HK1215185A1 (zh) 2016-08-19
CN104936609B (zh) 2017-04-12
NI201500100A (es) 2019-05-07
US20180280432A1 (en) 2018-10-04
NZ710691A (en) 2020-09-25
JP2016507527A (ja) 2016-03-10
MX2015009968A (es) 2016-03-11
CN107007624A (zh) 2017-08-04
EA201591424A1 (ru) 2015-12-30
JP2019151669A (ja) 2019-09-12
AU2014212127A1 (en) 2015-08-20
PH12015501708A1 (en) 2015-10-12
ZA201506364B (en) 2022-07-27
EP3789034A1 (en) 2021-03-10
WO2014121155A1 (en) 2014-08-07
EP2950806A1 (en) 2015-12-09
AU2018278891A1 (en) 2019-01-03
US20150366907A1 (en) 2015-12-24
EA032407B1 (ru) 2019-05-31
AU2020286223A1 (en) 2021-01-07
CL2015002171A1 (es) 2016-02-05
JP2021169525A (ja) 2021-10-28
CN104936609A (zh) 2015-09-23
AU2018278891B2 (en) 2020-09-10
CA2900043A1 (en) 2014-08-07
TW201517913A (zh) 2015-05-16
BR112015018549A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
BR112015018549A8 (pt) métodos de tratamento de deficiência de ferro
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12020500352A1 (en) Therapeutic uses of empagliflozin
MX2016007351A (es) Terapia de combinacion para tratar cancer.
BR112017011536A2 (pt) terapias de combinação
MX2019010601A (es) Terapia de combinacion para tratar cancer.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112017028132A2 (pt) métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MX2017013142A (es) Terapia combinada para tratar cáncer.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2016001446A (es) Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos.
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
WO2015035410A8 (en) Cancer therapy
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL